Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

Class:IdLiteratureReference:9702875
_displayNameIdentification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
_timestamp2020-10-02 17:59:05
author[Person:9699382] von Bubnoff, N
[Person:9702876] Rummelt, C
[Person:9702878] Menzel, H
[Person:9702877] Sigl, M
[Person:9699380] Peschel, C
[Person:9699377] Duyster, J
created[InstanceEdit:9702879] Rothfels, Karen, 2020-10-02
journalLeukemia
pages1523-5
pubMedIdentifier20520641
titleIdentification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
volume24
year2010
(literatureReference)[DefinedSet:9699529] midostaurin-sensitive FLT3 mutants [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9702909] FLT3 A848P [plasma membrane] [Homo sapiens]
[FailedReaction:9702623] sorafenib-resistant FLT3 mutants don't bind sorafenib [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib (9702875)